PT  - JOURNAL ARTICLE
AU  - Rosalba Mansi
AU  - Ryogo Minamimoto
AU  - Helmut Mäcke
AU  - Andrei H. Iagaru
TI  - Bombesin-Targeted PET of Prostate Cancer
AID  - 10.2967/jnumed.115.170977
DP  - 2016 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 67S--72S
VI  - 57
IP  - Supplement 3
4099  - http://jnm.snmjournals.org/content/57/Supplement_3/67S.short
4100  - http://jnm.snmjournals.org/content/57/Supplement_3/67S.full
SO  - J Nucl Med2016 Oct 01; 57
AB  - Imaging plays an important role in prostate cancer (PC), including accurate evaluation of the extent of disease, assessment of sites of recurrent disease, and monitoring of response to treatment. Molecular imaging techniques are among the novel developments related to the imaging of PC, and various SPECT and PET radiopharmaceuticals are now available in clinical trials or commercially. Here we describe the preclinical and clinical use of gastrin-releasing peptide receptors as targets for the imaging of PC, with a focus on the development of PET tracers for the imaging of gastrin-releasing peptide receptor–positive tumors.